Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Gross Profit Margin for the year ending December 31, 2023: 103.06%

Oncopeptides AB (publ) Gross Profit Margin is 103.06% for the year ending December 31, 2023, a 3.14% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Oncopeptides AB (publ) Gross Profit Margin for the year ending December 31, 2022 was 99.93%, a 81.38% change year over year.
Oncopeptides AB (publ) Gross Profit Margin for the year ending December 31, 2021 was 55.09%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years